Cargando…

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Tol, J., Cats, A., Mol, L., Koopman, M., Bos, M. M. E. M., van der Hoeven, J. J. M., Antonini, N. F., van Krieken, J. H. J. M., Punt, C. J. A.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480515/
https://www.ncbi.nlm.nih.gov/pubmed/18335169
http://dx.doi.org/10.1007/s10637-008-9125-4
Descripción
Sumario:Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a phase III multicentre trial which included chemotherapy and bevacizumab, who developed a GI ulcer (n = 6), perforation (n = 8) or both (n = 4). The risk of developing a symptomatic GI ulcer or perforation was 1.3% and 1.6%, respectively. Central review of the histology specimens showed ulceration and/or granulation tissue with neovascularisation. The majority (89%) of events developed early during treatment. Given these observations, as well as the relationship between VEGF and mucosal injury healing, we suggest that GI ulcers may occur as a side effect of treatment with bevacizumab and may herald perforation.